Saptalis Pharmaceuticals Launches Cyclosporine Ophthalmic Emulsion 0.05% and Expands Product Portfolio
Saptalis Pharmaceuticals LLC today announced the commercial launch of Cyclosporine Ophthalmic Emulsion 0.05%, available in 30- and 60-count single-use vials, reinforcing its commitment to expanding access to high-quality treatments.
Dry eye disease affects millions of patients worldwide. Cyclosporine Ophthalmic Emulsion 0.05% is a preservative-free, single-use formulation indicated to increase tear production and provides a convenient option for managing inflammation-associated tear deficiency.
In addition to Cyclosporine Ophthalmic Emulsion, Saptalis also announced the approval and launch of several other products across multiple therapeutic categories:
“With these launches, we continue to grow our generic business segment with U.S.-based manufacturing, while maintaining our primary focus on advancing our pipeline of innovative branded therapies addressing unmet medical needs,” said Polireddy Dondeti, President and CEO of Saptalis Pharmaceuticals LLC.
